Patients with cancer and a suppressed immune system are at high risk for severe COVID if treated with systemic drug therapies, study finds



Patients with cancer and a suppressed immune system are at high risk for severe COVID if treated with systemic drug therapies, study finds

Patients with cancer and a weakened immune system who are treated with immunotherapies tend to fare far worse from COVID-19 than those who haven’t received such therapies in the three months before their COVID diagnosis, show findings in a new study. Researchers found worse outcomes in both the disease itself as well as the fierce immune response that sometimes accompanies it.

Materials provided by Dana-Farber Cancer Institute. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

18th March 2023

New combination of drugs works together to reduce lung tumors in mice

Read more
17th March 2023

Study offers a potential strategy to improve T cell therapy in solid tumors

Read more
17th March 2023

Researchers chart a course for understanding, preventing, and treating young-onset colorectal cancer

Read more